Dr. Zhou has multi-discipline expertise from both academic and industrial background with over 20 years’ experience in drug discovery and development and he founded Danatlas Pharmaceuticals as Chairman and CEO in 2021. From 2015 to 2021, he served as SVP and CBO at Jacobio Pharmaceuticals, managing more than 10 R&D pipelines. Notably, he also directed the landmark licensing of SHP2 inhibitor program to AbbVie and co-led its advancement into Phase II trials as a JSC key member. Earlier at Novartis Oncology (2009-2015) as Lab Head, he successfully led several first-in-class small molecules and siRNA programs from target discovery to Phase I studies. He holds a Ph.D. in Molecular Biology from the University of Melbourne and completed postdoctoral training at UC San Diego School of Medicine, trained under internationally renowned scientist Michael G. Rosenfeld, a dual-elected member of the US National Academy of Sciences and National Academy of Medicine.

Li Hongmei currently serves as the Chief Operating Officer at Danatlas Pharmaceuticals. Li Hongmei has over 18 years’ experience of operational management in technology-driven R&D enterprises. She has deeply involved in the full-cycle of capitalization management of pharmaceutical companies such as Jacobio Pharmaceuticals (HKEX: 1167.HK) and Betta Pharmaceuticals (SZSE: 300558.SZ). She also established integrated risk control systems encompassing finance, human resources, legal affairs, and investment & financing. Li Hongmei previously served as Vice President of Jinlan Gene, Administrative Director & HR Director at Jacobio Pharmaceuticals, and Head of the HR Department in the New Drug R&D Center at Betta Pharmaceuticals. She played a key role in building internal control management systems of these companies, covering finance, legal affairs, human resources, government relations, investor relations, corporate planning, and brand development. She has extensive experience in corporation risk control, building international organizational system, and investment & financing. Li Hongmei holds a Master’s degree in Public Administration from Renmin University of China and a Bachelor’s degree in Accounting from the Department of Management, Chengdu University of Information Technology.

Dr. Tiansheng Wang has over 20 years of experience in medicinal chemistry, proficient in discovering new chemical entities through innovative approaches across therapeutic areas including oncology, metabolic diseases, central nervous system (CNS) disorders and anti-infectives. His key accomplishments include: leading the development of inaxaplin (VX-147), the first-in-class APOL1-targeted drug for kidney disease; Discovering the first-in-class antibiotics, topoisomerase B inhibitor VXc-486; Serving as a primary inventor of an EGFR L858R inhibitor, which was subsequently out-licensed by Allorion Therapeutics to AstraZeneca; Playing a leading role in advancing more than 10 novel drug molecules into clinical trials. Dr. Wang held positions as VP of Chemistry at Expansion Therapeutics, Senior Director of Medicinal Chemistry at Allorion Therapeutics and Director of Chemistry at Vertex Pharmaceuticals. Dr. Wang had his undergraduate degree from the Department of Chemistry at Nankai University and conducted postdoctoral research in medicinal chemistry at the University of Vermont.

Dr. Xi Chen has over 15 years of interdisciplinary R&D experience across Biology, DMPK, Toxicology, Clinical Translation and Regulatory Affairs. He has successfully advanced several programs into clinical development including two into Phase III trials, with therapeutic areas of oncology, autoimmune diseases, anti-infectives and metabolic disorders. At Sinovent/Evopoint, he led the preclinical and clinical translational research for the BTK inhibitor XNW1011, supporting the development for both oncology and autoimmune indications. XNW1001 was also the first clinical translational breakthrough in China for the application of BTK inhibitor in autoimmune diseases. This program has been successfully out-licensed to Everest Medicines. In addition, he directed the preclinical and PK/PD studies for the antibiotics program XNW4107, supporting its advance into global Phase III trial and subsequent NDA submission. Dr. Chen previously held positions at Sinovent/Evopoint, Biocytogen, and Zhongyuan Pharmaceuticals. Dr. Chen had his Ph.D. from the School of Medicine, University of Salamanca in Spain.